Clinical trial
Finding the Optimal Dose of Rivaroxaban in Hemodialysis Patients
NCT02047006 is registered in ClinicalTrials.gov with AZ Sint-Jan AV as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Finding the Optimal Dose of Rivaroxaban in Hemodialysis Patients
- Lead sponsor
- AZ Sint-Jan AV
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- September 30, 2013
- Completion date
- October 31, 2014
- Enrollment
- 18 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.
chronic renal failure